Nakazono Kenichi, Saito Hiroki, Ohkubo Ayaka, Onodera Hidetaka, Wakatake Haruaki, Katsuta Yuta, Tada Junpei, Kunishima Hiroyuki, Matsuzaki Takashi
Department of Pharmacy, St. Marianna University Yokohama Seibu Hospital, Yokohama, Kanagawa, Japan.
Infection Control Division, St. Marianna University Yokohama Seibu Hospital, Yokohama, Kanagawa, Japan.
IDCases. 2024 Jul 20;37:e02035. doi: 10.1016/j.idcr.2024.e02035. eCollection 2024.
The area under the concentration-time curve (AUC)/minimum inhibitory concentration (MIC) - guided approach is recommended for vancomycin therapeutic drug monitoring in severe methicillin-resistant (MRSA) infection. However, evidence regarding the efficacy of vancomycin AUC-guided strategies for the treatment of systemic infections is limited. This case report describes the successful treatment of MRSA meningitis, with vancomycin using a higher AUC/MIC target. A 61-year-old woman who underwent ventriculoperitoneal (VP) shunt placement for subarachnoid hemorrhage, developed MRSA meningitis due to shunt infection. Vancomycin was administered intravenously, with concurrent monitoring of serum and cerebrospinal fluid (CSF) vancomycin concentrations and AUC/MIC. On post-operative day (POD) 24 of VP shunt placement, the vancomycin trough concentration and AUC/MIC were 12.0 μg/mL and 515, respectively, with persistently positive CSF culture. On POD 28, the trough concentration and AUC/MIC were 18.6 μg/mL and 610, respectively. There were no major adverse events, and CSF culture turned negative on POD 30. The vancomycin CSF-to-serum ratio was approximately 41 %. For patients with MRSA meningitis, we suggest an optimal therapeutic range with a vancomycin AUC/MIC target near the upper limit of the therapeutic window.
在严重耐甲氧西林金黄色葡萄球菌(MRSA)感染中,推荐采用浓度-时间曲线下面积(AUC)/最低抑菌浓度(MIC)指导的方法进行万古霉素治疗药物监测。然而,关于万古霉素AUC指导策略治疗全身感染疗效的证据有限。本病例报告描述了使用较高AUC/MIC目标的万古霉素成功治疗MRSA脑膜炎的情况。一名61岁女性因蛛网膜下腔出血接受脑室腹腔(VP)分流术,因分流感染发生MRSA脑膜炎。静脉注射万古霉素,同时监测血清和脑脊液(CSF)万古霉素浓度及AUC/MIC。在VP分流术后第24天(POD),万古霉素谷浓度和AUC/MIC分别为12.0μg/mL和515,脑脊液培养持续阳性。在POD 28,谷浓度和AUC/MIC分别为18.6μg/mL和610。未发生重大不良事件,POD 30时脑脊液培养转阴。万古霉素脑脊液与血清的比值约为41%。对于MRSA脑膜炎患者,我们建议万古霉素AUC/MIC目标在治疗窗上限附近的最佳治疗范围。